

The dynamic map of treatment for SCCHN:

The optimal pathway for your patient

Merck, along with a panel of leading experts, invite you to join them at this satellite symposium

Available on demand from:
14 September, 2020
09:00 CET

Chair: **Jan Vermorken**

Speakers: **Miren Taberna and Ana Castro**

AGENDA

Presentation

Welcome and introduction
by the Chair

Speakers and Chair

Jan Vermorken

A new treatment
landscape in SCCHN:
Personalizing patient care

Jan Vermorken

Guiding Erbitux treatment
according to patients'
needs in R/M SCCHN

Miren Taberna

Every step in the
treatment journey is
important in R/M SCCHN

Ana Castro

Live discussion and Q&A with our panel of leading
experts: 17:00–17:30 CET, 18 September, 2020

Full product information for the European Economic Area is available at the EMA website. Please contact the local representative in your country for the respective Product Information. For HCPs from Switzerland, please be aware of the following information: Erbitux is approved in Switzerland in combination with radiation therapy for the treatment of patients with locally advanced squamous cell cancer of the head and neck. In combination with cisplatin and 5-fluorouracil for the treatment of patients with recurrent and/or metastatic squamous cell cancer of the head and neck. Erbitux is administered once a week. Full professional information is available from swissmedicinfo.

This symposium is a Global event
sponsored by Merck
GL-ERBSCCHN-00064
Date of preparation: September 2020